Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January

Celcuity Inc. (NASDAQ:CELC - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, an increase of 6.4% from the January 15th total of 3,130,000 shares. Based on an average daily trading volume, of 283,600 shares, the days-to-cover ratio is presently 11.7 days.

Institutional Investors Weigh In On Celcuity

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in Celcuity by 2,083.4% during the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company's stock worth $673,000 after buying an additional 43,044 shares in the last quarter. Geode Capital Management LLC grew its position in Celcuity by 27.6% during the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company's stock worth $9,401,000 after buying an additional 136,518 shares in the last quarter. State Street Corp grew its position in Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company's stock worth $16,512,000 after buying an additional 668,318 shares in the last quarter. Braidwell LP grew its position in Celcuity by 71.2% during the third quarter. Braidwell LP now owns 884,306 shares of the company's stock worth $13,185,000 after buying an additional 367,663 shares in the last quarter. Finally, Barclays PLC grew its position in Celcuity by 567.6% during the third quarter. Barclays PLC now owns 53,605 shares of the company's stock worth $800,000 after buying an additional 45,576 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CELC shares. Needham & Company LLC boosted their price target on Celcuity from $23.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $30.17.

Celcuity Stock Performance

Shares of Celcuity stock traded up $0.02 on Friday, hitting $13.15. The stock had a trading volume of 314,051 shares, compared to its average volume of 232,809. Celcuity has a twelve month low of $10.35 and a twelve month high of $22.19. The business's 50 day moving average is $12.28 and its two-hundred day moving average is $14.05. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $488.26 million, a price-to-earnings ratio of -5.04 and a beta of 0.73.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.